Clinical trials: CAEBV
CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, PTLDs
Clinical Study of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
This study intends to conduct a prospective single-center open single-arm multi-dose escalation study on therapeutic immunological agent treatment in patients with Lymphoproliferative disease associated with EBV to observe the…
- Trial name
- NCT06666153
- Testing
- EBV immunological agent
- Where
- China
- Volunteers
- 27 people
- Sponsor
- West China Hospital
Lymphohistiocytosis, EBV
Golidocitinib Combined With Selinexor for CAEBVD
This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.
- Conditions
- Lymphohistiocytosis, EBV, CAEBV
- Trial name
- NCT07369739
- Testing
- golidocitinib, Selinexor (combination therapy)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Beijing Friendship Hospital
Chronic Active Epstein-Barr Virus Infection, Virus-Associated Hemophagocytic Syndrome
Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT
To evaluate the efficacy and safety of donor EBV-specific T lymphocytes (EBV-CTL) infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after…
- Trial name
- NCT05532826
- Testing
- donor EBV-specific T lymphocytes
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Friendship Hospital
EBV Infection
Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy
EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the most effective treatment remains unknown.
- Trial name
- SEHC (NCT05039580)
- Testing
- PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The First Affiliated Hospital of Soochow University
PTLD, CAEBV
Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of PTLD in Patients With EBV-HLH/CAEBV
This is a clinical study on the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
- Conditions
- PTLD, CAEBV, HLH
- Trial name
- NCT05258136
- Testing
- low-dose CD20 monoclonal antibody injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Rituximab Monotherapy for EBV-HLH and CAEBV
This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV…
- Trial name
- NCT05384743
- Testing
- Rituximab Monotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Friendship Hospital
CAEBV
Selinexol Combined With Dexamethasone in the Treatment of CAEBV
This study is a single-center, prospective, observational clinical study to evaluate the Effecive and Safty of Selinexol and Dexamethasone in CAEBV
- Trial name
- NCT05347381
- Testing
- Selinexol and Dexamethasone
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Beijing Friendship Hospital
PD-1, EBV Infection
PD-1 Antibody for Reactive EBV After BMT
PD-1 antibody for reactivation of EBV after transplantation in patients with CAEBV/EBV-HLH
- Conditions
- PD-1, EBV Infection, Transplant
- Trial name
- NCT04690036
- Testing
- toripalimab injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
EBV Infection
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
The present study was a prospective one-arm clinical study, in which EBV-HLH/chronic active EBV infection patients were selected as the main subjects to evaluate the effect of PD-1 antibody and lenalidomide regimens on ebv-dna…
- Trial name
- NCT04084626
- Testing
- PD1 antibody, lenalidomide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Friendship Hospital
CAEBV
Sintilimab and Lenalidomide as a Treatment for CAEBV
This study is a multi-center, prospective, randomized, controlled clinical study to evaluate the effectiveness of a combination regimen of Sintilimab and lenalidomide in patients with chronic active EBV infection.
- Trial name
- NCT04518982
- Testing
- Sintilimab and lenalidomide
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Zhao Wang
CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, EBV
A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT
To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem…
- Conditions
- CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome, EBV, Hemophagocytic Lymphohistiocytoses
- Trial name
- NCT06491719
- Testing
- NCR300（Allogenic Ipsc-derived Natural Killer cells ）
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Beijing Friendship Hospital
Secondary Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients
This prospective case-control study aims to evaluate the immune function and find PD-1 antibody efficacy predictors on Chronic Active Epstein-Barr Virus Infection and Epstein-Barr virus-associated hemophagocytic…
- Trial name
- NCT05841342
- Testing
- No intervention
- Where
- China
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Chronic Active Epstein-Barr Virus
Genetic Studies of Chronic Active Epstein-Barr Disease
Epstein-Barr virus (EBV) is a member of the human herpes virus family that infects more than 95 percent of the U.S. population. Most infections occur in childhood and cause no symptoms; in adolescents and adults, EBV often causes…
- Trial name
- NCT00032513
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)